1 - 22 of 22
Dr. MacFarland's research focuses on syndromes that predispose to cancer development in children and adolescents. She has initiated several individual and collaborative research projects, working in pediatric polyposis syndromes and Li-Fraumeni syndrome. She is uncovering novel genomic drivers of disease and identifying biomarkers of cancer onset and progression.
Dr. Marks investigates the molecular mechanisms underlying the formation of cell type-specific lysosome-related organelles; the assembly, delivery and function of their contents; and how these processes are impacted by genetic diseases.
Dr. Marsh's research program focuses on understanding how changes in brain development lead to epilepsy, intellectual disability, and autism. He combines molecular and physiological tools in mouse models to ask questions about the interaction of normal development with single gene mutations to determine how the brain responds to perturbations in development.
Dr. Mascarenhas is director of the Nutrition Support Service, section chief of nutrition in the Division of Gastroenterology and Nutrition, medical director of the Clinical Nutrition Department, and director of the Integrative Health Program. Her research interests involve 22q deletion syndrome, cystic fibrosis, nutrition, and integrative medicine.
Dr. Maude focuses on novel therapies for high-risk and relapsed pediatric acute lymphoblastic leukemia (ALL). She aims to identify new pediatric ALL treatments that are more effective, less toxic, and exhibit fewer side effects than existing cancer therapies.
Dr. McCormack investigates the intersection of neuroendocrinology and metabolism. Her translational research program involves two areas. The first involves studying those with genetic disorders, including primary mitochondrial diseases and Friedreich's ataxia, with characterized risk for diabetes mellitus. Second, Dr. McCormack focuses on brain disorders associated with excess weight gain, including brain tumor-related hypothalamic obesity syndrome and idiopathic intracranial hypertension.
Dr. Monos is an internationally recognized expert on histocompatibility (HLA) molecules. His work covers a wide spectrum of HLA-related issues that pertain to both the molecular (structure/function) aspects of HLAs, as well as the genetics of the major histocompatibility complex, that includes the genes encoding the HLA molecules.
Dr. Mossé's research goal is to improve cure rates for the childhood cancer neuroblastoma by discovering the genetic basis of the disease and translating rational therapeutic opportunities to the clinic. She studies the contribution of DNA sequence variations and activation mutations of anaplastic lymphoma kinase (ALK) genes on the development and progression of both inherited and acquired forms of neuroblastoma.
The research conducted by Dr. Myers focuses on the identification and implementation of hospital-level factors that improve outcomes for seriously sick or injured children, as well as those who have time-sensitive and acute-care responsive disease processes.